Choosing Wisely: If, When, What, and Who to Test for Thrombophilia
|
|
- Isaac Blankenship
- 6 years ago
- Views:
Transcription
1 Choosing Wisely: If, When, What, and Who to Test for Thrombophilia Nicole Dodge Zantek, MD, PhD Medical Director, Special Coagulation Laboratory University of Minnesota
2 Disclosures Financial interests = ENDO International PLC, Boston Scientific Research Funding = Terumo BCT, Bayer HealthCare, Octapharma Advisory boards = NASCOLA Executive Committee, CAP Transfusion Medicine Resource Committee, ASCP Choosing Wisely Advisory Board
3 Thrombophilia hereditary or acquired increased risk for thrombosis
4 Venous Thromboembolism (VTE) Annual incidence rate VTE among persons of European ancestry = per 100,000 person yrs Leg DVT = per 100,000 person yrs PE ±DVT = per 100,000 person yrs ~100,000 deaths per year in US Increases with age Starting in 40 s and further increases in 60 s 25-40% estimated to be unprovoked Heit et al. J Thromb Thrombolysis 2016;41:3-14 Silverstein et al. Arch Int Med 1998;158;
5 Predisposing Factors Smoking Immobillization Inherited Causes Age >65 Years Trauma BMI >30 kg/m 2 Surgery Infection PNH VTE Pregnancy- Puerperium Medications Nephrotic Syndrome Antiphospholipid Antibodies Myeloproliferative Neoplasms Post Thrombotic Disorders Varicosis Malignancy Inflammatory States Colucci and Tsakiris. Clin Appl Thromb/Hemost 2017:23:
6 Heritable Thrombophilia Varies by population studied 4-10% of general population ~50% of patients with VTE Salvagno et al. Blood Transfus 2007; 5: Eid and Rihani. Clin Lab Sci 2004; 17: Weitz et al. Hematology (Am Soc Hematol Educ Program) 2004;
7 Prevalence of Thrombophilia Thrombophilia Prevalence Relative Risk of Initial VTE (Absolute Annualized Risk) Factor V Leiden (FVL) heterozygous 2-7% ( %) FVL homozygous % (0.8%) Prothrombin gene mutation (PGM) heterozygous 1-2% (0.13%) PGM homozygous Rare Compound FVL and PGM heterozygosity 0.1% (0.42%) Protein C deficiency % 10 ( %) Protein S deficiency % 9.6 ( %) Antithrombin deficiency 0.02% ( %) Antiphospholipid syndrome 2% 7 Data from several sources summarized by Stevens et al. J Thromb Thrombolysis 2016;41:
8 To Test or Not To Test?
9 Cons Inappropriate withholding or provision of anticoagulant High number to test to avoid 1 VTE High number to test to identify 1 thrombophilia Spurious results Misinterpretation of results Patient distress and anxiety Genetic discriminations Spurious results Pros Patient satisfaction of identifying risk factor Improve anticoagulant compliance Stevens et al. J Thromb Thrombolysis 2016;41: Middeldorp. Hematology Am Socl Hematol Educ Program 2016;2016:1-9
10 Does testing for thrombophilia Identify an increased risk for recurrent VTE? Guide anticoagulant therapy duration? Identify an increased risk for first VTE?
11 Recurrence ~30% in the next 10 years Highest incidence within first 6-12 months Higher in unprovoked VTE 10% 1 st year, 40% 5 years Low in provoked VTE 0-0.7% at 2 years post surgical Heit et al. J Thromb Thrombolysis 2016;41:3-14 Prandoni et al. Haematologica 2007;92: Baglin et al. Lancet 2003; 362: Iorio et al. Arch Intern Med 2010;170:
12 Predicting Recurrence Predictors of recurrence = increasing age, body mass, male, active cancer, neurologic disease with leg paresis Prediction scores (DASH, Vienna prediction model, HERDOO2) do not include thrombophilia testing Heit et al. J Thromb Thrombolysis 2016;41:3-14 Tosetto et al. J Thromb Haemost 2012; 10: Eichinger et al. Circulation 2010;121: Rodger et al. CMAJ 2008; 179:
13 Follow-Up from LETS Study Recurrence, per 1000 person years (95% CI) Recurrence with thrombophilia, per 1000 person years (95% CI) Recurrence without thrombophilia per 1000 person years (95% CI) Adjusted hazard ratio for thrombophilia (95% CI) Provoked Unprovoked 17.7 ( ) 33.2 ( ) 20.9 ( ) 33.6 ( ) 12.6 ( ) 32.4 ( ) 1.7 ( ) 1.2 ( ) Adjusted Hazard Ratio for Recurrence - Any abnormality 1.4 ( ) - FVL = 1.3 ( ) - PGM = 0.7 ( ) - Protein C, protein S, antithrombin= 1.8 ( ) Christiansen et al. JAMA 2005;293:
14 Addenbrook s Hospital - UK 570 patients Cumulative recurrence rate 11% at 2 years Low recurrence rate in post operative VTE 20% cumulative recurrence risk at 2 years for unprovoked Hazard ratio for presence of thrombophilia 1.50 (95% CI ) FVL 1.35 (95% CI ) PGM 1.74 (95% CI ) Baglin et al. Lancet 2003;362:523-6
15 Relative Risk of Recurrent VTE Thrombophilia Factor V Leiden (FVL) heterozygous FVL homozygous 1.8 Prothrombin gene mutation (PGM) heterozygous PGM homozygous Compound FVL and PGM heterozygosity Relative Risk of Recurrent VTE Uncertain 2.7 Protein C deficiency 1.8 Protein S deficiency 1.0 Antithrombin deficiency 2.6 Antiphospholipid syndrome Data from several sources summarized by Stevens et al. J Thromb Thrombolysis 2016;41:
16 Prevalence and Relative Risk Prevalence in general population Prevalence in consecutive patients with VTE Relative Risk for 1 st VTE Relative Risk for Recurrent VTE Antithrombin Deficiency Protein C Deficiency Protein S Deficiency 0.02% 0.2% % Factor V Leiden Prothrombin 20210A Mutation 3-7% 0.7-4% 1% 3% 2% 20% 5% Middeldorp Hematology Am Soc Hematol Educ Program 2016;2016(1):1-9 Middeldorp and van Hylckama Vlieg. Br J Haematol 2008;143:321-35
17 Thrombophilia Testing and Recurrence MEGA study case control substudy 197 with recurrence (case) vs 324 without (controls) Thrombophilia testing 35% case vs 30% control OR for recurrence Testing = 1.2 (95% CI ) FVL or PGM mutation = 0.8 (95% CI ) Coppens et al. J Thromb Haemost 2008;6:
18 Randomized Control Trial? No RCT has been completed to evaluate the role of thrombophilia testing with initial VTE NOSTRADAMUS study terminated early due to poor enrollment and lack of funding.
19 Anticoagulation Provoked VTE low risk of recurrence, complete 3 months anticoagulation Unprovoked VTE extended duration, unless bleeding risk high RCT placebo vs warfarin after 3 months anticoagulation for unprovoked VTE Trial ended early VTE in 27.4% per patient year placebo vs 1.3% per patient year warfarin Kearon et al. Chest 2016;149: Kearon et al. N Engl J Med 1999;340:901-7 Stevens et al. J Thromb Thrombolysis 2016;41:154-64
20 Extended Anticoagulation Risk of recurrence vs. bleeding Patient preference Prediction Age, gender, BMI Recurrence predictor scores (DASH, HERDOO2) D-dimer Residual venous occlusion Malignancy Thrombophilia
21 Family History 314 patients with DVT and/or PE recruited from 3 prospective studies in the Netherlands 190 had full thrombophilia testing 62 (33%) had 1 factor, 5 (3%) had 2 factors Thrombophilia present in 42% with positive vs. 32% with negative family history [likelihood ratio 1.3 (95% CI ) Family history score correlated with thrombophilia [odds ratio 1.23 per score point (95% CI )] chance of inherited thrombophilia is <50% in 97% of cases Sluis et al. J Thromb Haemost 2006;4:2182-7
22 Family History Increases risk for VTE - odds ratio 2.2 (95% CI ) When more than 1 relative affected odds ratio 3.9 (95% CI ) VTE at a young age and unprovoked VTE are independent predictors of VTE in patient relatives Bezemer et al. Arch Int Med 2009;169:610-5 Couturaud Blood 2014;124:
23 Thrombophilia Testing and Outcomes No impact on survival in patients with VTE No impact on risk of post thrombotic syndrome Reitter-Pfoertner et al. Thromb Haemost 2013;109:79 84 Rabinovich et al. J Thromb Haemost 2014;12:14 23
24 Guidelines American College of Chest Physicians Anticoagulation Forum British Committee for Standards in Hematology Choosing Wisely American Society of Hematology, Society for Vascular Medicine, American Society for Clinical Pathology, American College of Medical Genetics and Genomics, American Society for Reproductive Medicine, Society for Maternal Fetal Medicine Choosing Wisely Canada College of American Pathologists Evaluation of Genomic Applications in Practice and Prevention Working Group French Consensus Guidelines International Consensus Statement National Institute for Health and Clinical Excellence (NICE)
25 Guidelines Guideline Source Provoked VTE Unprovoked VTE Anticoagulation Forum (2016) Do not screen Screen highly select few American College of Chest Physicians (2012/2016) Do not screen Do not screen International Consensus Statement (2013) Selective screening Screen most or all National Institute for Health and Clinical Excellence (2012) Evaluation of Genomic Applications in Practice and Prevention Working Group (2011) Do not screen Do not screen Screen highly select few Do not screen British Committee for Standards in Hematology (2010) Do not screen Do not screen French Consensus Guideline (2009) Do not screen Screen most or all Stevens and Ansell. Semin Respir Crit Care Med 2017;38:107 20
26 Who to Test Provoked do not test Unprovoked selected patient testing if considering stopping anticoagulant First degree, asymptomatic relatives selected patient testing Primary prevention OCP/HRT Pregnancy
27 Connors. ThrombophiliaTesting and Venous Thrombosis. N Engl J Med 2017;377:12 Massachusetts Medical Society Reprinted with permission
28 Testing Issues
29 What to Test Factor V Leiden gene mutation Prothrombin gene mutation Protein C chromogenic activity (or clot based protein C activity) Protein S free antigen (or clot based protein S activity) Antithrombin chromogenic activity Antiphospholipid antibodies Lupus anticoagulant Beta 2 glycoprotein 1 IgG and IgM Cardiolipin IgG and IgM
30 What Not to Test Factor VIII Factor IX Factor XI Plasminogen activator inhibitor-1 MTHFR polymorphisms Tissue plasminogen activator
31 Testing Pitfalls Possible False Diagnosis Thrombophilia frequency in population Reference range Accuracy and precision of assays Methodologic differences Preanalytic issues Timing of testing Anticoagulant Favaloro et al. Semin Thromb Hemost 2009;35: Favaloro et al. Semin Thromb Hemost 2008;34:612-34
32 Test Variation Lessons Learned from Proficiency Testing High variation in thrombophilia testing ~5-20% Incorrect diagnosis UK NEQAS thrombophilia exercises ( ) 5.5% for normal plasma 37.8% for FVL homozygous Royal College of Pathologists of Australasia Quality Assurance Program 2-8% Jennings et al. Semin Thromb Hemost 2005;31:66-72 Meijer and Haverkate. Semin Thromb Hemost 2005;31:59-65 Favaloro et al. Semin Thromb Hemost 2005; Cunningham et al Arch Pathol Lab Med. 2011;135: Baron et al Am J Clin Pathol 2012;137: Smock et al. Thromb Haemost 2016;116:50-7
33 Methodologic Issues APCR/FVL false decrease in protein S activity in some assays Lupus anticoagulant false elevation of proteins C and S by clot based assays Lupus anticoagulant, factor inhibitor, factor deficiency false APCR results Protein C and protein S antigens may miss some variants detected by activity FVL may be missed in some APCR assays without predilution with Factor V deficient plasma FVL genetics misses other causes of APCR resistance detected by APCR assay Smock et al.thromb Haemost 2016;116:50-7 Favaloro et al. Semin Thromb Hemost 2009;35: Favaloro et al. Pathology 2002;34: Favaloro et al. Semin Thromb Hemost 2005;31:49-58
34 When to Test and Acute Clot Genetic testing unaffected Protein C, proteins S, and antithrombin decreased Lupus anticoagulant may be transiently elevated Moll. J Thromb Thrombolysis 2015;39:
35 Anticoagulants and Testing Vitamin K Antagonist Unfractionated Heparin Direct Factor Xa Inhibitors Direct Thrombin Inhibitors Lupus anticoagulant Possible false + Possible false + Possible false + Possible false + APCR clot based Variable Possible false Possible false Possible false Antithrombin factor IIa NC NC - # NC False based* Antithrombin factor Xa NC NC- # False NC based Protein C activity * NC NC NC chromogenic Protein C activity clot * Possible false False False based Protein S free protein * NC NC NC S antigen Protein S activity clot * Possible false False False based Protein S total antigen * NC NC NC NC = no change *Expected physiologic response to vitamin K antagonists. # Heparin may cause a physiologic decrease in antithrombin. Goodwin and Adcock. N Engl J Med 2017;377:23 Favaloro and Lippi Blood Transfus 2017;15: Funk Hematology Am Soc Hematol Educ Program 2012;2012:460-5
36 Anticoagulants and Testing No Effect Factor V Leiden genetic testing Prothrombin G20210A genetic testing Fibrinogen antigen D-dimer Von Willebrand factor testing Anti-Cardiolipin Anti-Beta2 glycoprotein 1
37 When to Test Consider 2 stage testing 1 st FVL, PGM, cardiolipin antibodies, β2 glycoprotein 1 antibodies If negative stop anticoagulation for 2-4 weeks 2 nd Protein C, protein S, antithrombin, lupus anticoagulant Stevens and Ansell. Semin Resp Crit Care Med 2017;38:107-20
38 Inappropriate Testing Somma et al. Am J Clin Pathol 2006;126: consecutive thrombophilia panels 62% ordered during acute thrombotic event 12.5% had abnormal protein C or S results due to warfarin 7.5 % abnormal protein S due to pregnancy/intrauterine fetal demise Shen et al. Plos One 2015:11(5);e patients tested 51% tested within 1 week of index clinical event 34% had appropriate indication: unprovoked venous or arterial thrombosis or pregnancy losses 34% tested while on anticoagulation
39 Cost In 2014, 280,000 claims were made to Medicare an estimated cost of $ million A single center study Implementation of testing guidelines 84% reduction in testing Projected wastage >$1 million/year Petrilli et al J Hosp Med 2016;11:801-4 Shen et al Plos One 2015:11:e
40 Two Sides to the Story Many patients with a heritable thrombophilia never develop a VTE. Negative thrombophilia testing does not equal low risk for VTE.
41 Conclusions Thrombophilia testing should not be routinely ordered for all patients, Testing should only be obtained in selected patients. Testing should only be obtained if it will influence management decisions. Beware of issues with testing, particularly in relation to timing of thrombosis and anticoagulant use.
Scott M. Stevens, MD. Co-Director, Thrombosis Clinic. Associate Professor of Clinical Medicine
Scott M. Stevens, MD Co-Director, Thrombosis Clinic Intermountain Medical Center Associate Professor of Clinical Medicine The University of Utah School of Medicine No Relevant Financial Relationships Research
More informationThrombophilia: To test or not to test
Kenneth Bauer, MD Harvard Medical School, Boston, MA Professor of Medicine VA Boston Healthcare System Chief, Hematology Section Beth Israel Deaconess Medical Center, Boston, MA Director, Thrombosis Clinical
More informationInherited Thrombophilia Testing. George Rodgers, MD, PhD Kristi Smock MD
Inherited Thrombophilia Testing George Rodgers, MD, PhD Kristi Smock MD Prevalence and risk associated with inherited thrombotic disorders Inherited Risk Factor % General Population % Patients w/ Thrombosis
More informationThrombophilia. Diagnosis and Management. Kevin P. Hubbard, DO, FACOI
Thrombophilia Diagnosis and Management Kevin P. Hubbard, DO, FACOI Clinical Professor of Medicine Kansas City University of Medicine and Biosciences-College of Osteopathic Medicine Kansas City, Missouri
More informationThrombophilia. Stephan Moll, MD Medicine, Heme-Coag UNC Chapel Hill, NC. GASCO Atlanta Sept 8 th, Disclosures. Conflicts of interest: NONE
LA APLA 1 3 ACA Anti-ß2-GP I 2 45 Thrombophilia Stephan Moll, MD Medicine, Heme-Coag UNC Chapel Hill, NC GASCO Atlanta Sept 8 th, 2017 Disclosures Conflicts of interest: NONE Off-label product use discussion:
More informationTHROMBOPHILIA TESTING: PROS AND CONS SHANNON CARPENTER, MD MS CHILDREN S MERCY HOSPITAL KANSAS CITY, MO
THROMBOPHILIA TESTING: PROS AND CONS SHANNON CARPENTER, MD MS CHILDREN S MERCY HOSPITAL KANSAS CITY, MO DISCLAIMER I m a pediatrician I will be discussing this issue primarily from a pediatric perspective
More informationOptimal Utilization of Thrombophilia Testing
Optimal Utilization of Thrombophilia Testing Rajiv K. Pruthi, MBBS Special Coagulation Laboratory & Comprehensive Hemophilia Center Division of Hematology/Internal Medicine Dept of Laboratory Medicine
More informationConsultative Coagulation How to Effectively Answer Common Questions About Hemostasis Testing Session #5000
Consultative Coagulation How to Effectively Answer Common Questions About Hemostasis Testing Session #5000 Dorothy M. (Adcock) Funk, M.D. Karen A. Moser, M.D. Esoterix Coagulation September 20, 2013 Disclosures
More informationMabel Labrada, MD Miami VA Medical Center
Mabel Labrada, MD Miami VA Medical Center *1-Treatment for acute DVT with underlying malignancy is for 3 months. *2-Treatment of provoked acute proximal DVT can be stopped after 3months of treatment and
More informationDuration of Therapy for Venous Thromboembolism
Duration of Therapy for Venous Thromboembolism Michael B Streiff, MD FACP Associate Professor of Medicine and Pathology Medical Director, Johns Hopkins Anticoagulation Service Chairman, VTE Guideline Committee
More informationUpdates in Diagnosis & Management of VTE
Updates in Diagnosis & Management of VTE TRACY MINICHIELLO, MD CHIEF, ANTICOAGULATION& THROMBOSIS SERVICE-SAN FRANCISCO VAMC PROFESSOR OF MEDICINE UNIVERSITY OF CALIFORNIA, SAN FRANCISCO Financial Disclosures-NONE
More informationOriginal Policy Date
MP 2.04.71 Genetic Testing for Inherited Thrombophilia Medical Policy Section Medicine Issue 12:2013 Original Policy Date 12:2013 Last Review Status/Date Created with literature search12:2013 Return to
More informationDuration of anticoagulation
Duration of anticoagulation P. Fontana Service d angiologie et d hémostase Hôpitaux Universitaires de Genève Pomeriggio formativo in coagulazione, Bellinzona, 19.10.2017 Conflict of interest AstraZeneca,
More informationLaboratory Evaluation of Venous Thrombosis Risk
Laboratory Evaluation of Venous Thrombosis Risk Dorothy M. Adcock, MD Volume 17, Number 12 December 2003 Objective: The reader will be able to discuss the concepts of risk factor, risk potential and thrombotic
More informationDuration of Anticoagulant Therapy. Linda R. Kelly PharmD, PhC, CACP September 17, 2016
Duration of Anticoagulant Therapy Linda R. Kelly PharmD, PhC, CACP September 17, 2016 Conflicts of Interest No conflicts of interest to report Objectives At the end of the program participants will be
More informationGenetic Tests for the Better Outcome of VTE? 서울대학교병원혈액종양내과윤성수
Genetic Tests for the Better Outcome of VTE? 서울대학교병원혈액종양내과윤성수 Thrombophilia A hereditary or acquired disorder predisposing to thrombosis Questions Why should we test? Who should we test For what disorders?
More informationPredicting the risk of recurrent venous thromboembolism (VTE)
J Thromb Thrombolysis (2015) 39:353 366 DOI 10.1007/s19-015-1188-4 Predicting the risk of recurrent venous thromboembolism (VTE) Michael B. Streiff Published online: 27 February 2015 Ó Springer Science+Business
More informationApproach to Thrombosis
Approach to Thrombosis Theera Ruchutrakool, M.D. Division of Hematology Department of Medicine Siriraj Hospital Faculty of Medicine Mahidol University Approach to Thrombosis Thrombosis: thrombus formation
More informationAre there still any valid indications for thrombophilia screening in DVT?
Carotid artery stenosis and risk of stroke Are there still any valid indications for thrombophilia screening in DVT? Armando Mansilha MD, PhD, FEBVS Faculty of Medicine of University of Porto Munich, 2016
More informationDave Duddleston, MD VP and Medical Director Southern Farm Bureau Life
Dave Duddleston, MD VP and Medical Director Southern Farm Bureau Life Sources of Risk for Venous Diseases Pulmonary embolism (thrombus) Bleeding from anticoagulation Mortality from underlying disease Chronic
More informationTHROMBOPHILIA SCREENING
THROMBOPHILIA SCREENING Introduction The regulation of haemostasis Normally, when a clot occurs, it exactly occurs where it has to be and does not grow more than necessary due to the action of the haemostasis
More informationDuration of Anticoagulation? Peter Verhamme MD, PhD Department of Cardiovascular Medicine University of Leuven Belgium
Duration of Anticoagulation? Peter Verhamme MD, PhD Department of Cardiovascular Medicine University of Leuven Belgium Disclosures Honoraria and research support: Daiichi-Sankyo, Boehringer Ingelheim,
More informationDiagnosis and management of heritable thrombophilias
Link to this article online for CPD/CME credits Diagnosis and management of heritable thrombophilias Peter MacCallum, 1 2 Louise Bowles, 2 David Keeling 3 1 Wolfson Institute of Preventive Medicine, Barts
More informationMenopausal Hormone Therapy & Haemostasis
Menopausal Hormone Therapy & Haemostasis The Haematologist Perspective Dr. Batia Roth-Yelinek Coagulation unit Hadassah MC Menopausal Hormone Therapy & Hemostasis Hemostatic mechanism Mechanism of estrogen
More informationDISCLOSURE. Presented by: Merav Sendowski, MD Oregon Health and Science University
Thrombophilia! DISCLOSURE Presented by: Merav Sendowski, MD Oregon Health and Science University Created by: Thomas Deloughery, MD Oregon Health and Science University Current Relevant Financial Relationship(s)
More informationVENOUS THROMBOEMBOLISM AND CORONARY ARTERY DISEASE: IS THERE A LINK?
VENOUS THROMBOEMBOLISM AND CORONARY ARTERY DISEASE: IS THERE A LINK? Ayman El-Menyar (1), MD, Hassan Al-Thani (2),MD (1)Clinical Research Consultant, (2) Head of Vascular Surgery, Hamad General Hospital
More informationStanford University H IGH VALUE C ARE: OPTIMAL A PPROACH. Andre Kumar MD Tyler Johnson MD Neil Shah MD Jason Hom MD
Stanford University H IGH VALUE C ARE: OPTIMAL A PPROACH TO T HROMBOPHILIA W ORKUPS & FRESH F ROZEN P LASMA U SE Andre Kumar MD Tyler Johnson MD Neil Shah MD Jason Hom MD Learning Objectives AFTER COMPLETION
More informationHemostasis. PHYSIOLOGICAL BLOOD CLOTTING IN RESPONSE TO INJURY OR LEAK no disclosures
Hemostasis PHYSIOLOGICAL BLOOD CLOTTING IN RESPONSE TO INJURY OR LEAK no disclosures Disorders of Hemostasis - Hemophilia - von Willebrand Disease HEMOPHILIA A defect in the thrombin propagation phase
More informationUC SF. Division of General Internal Medicine UNIVERSITY OF CALIFORNIA SAN FRANCISCO, DIVISION OF HOSPITAL MEDICINE
Updates in the Management of Venous Thromboembolism Margaret C. Fang, MD, MPH Associate Professor of Medicine UCSF Division of Hospital Medicine Medical Director, Anticoagulation Clinic Venous Thromboembolism
More informationDEEP VEIN THROMBOSIS (DVT): TREATMENT
DEEP VEIN THROMBOSIS (DVT): TREATMENT OBJECTIVE: To provide an evidence-based approach to treatment of patients presenting with deep vein thrombosis (DVT). BACKGROUND: An estimated 45,000 patients in Canada
More informationThrombophilia Testing and Venous Thrombosis
Review Article Dan L. Longo, M.D., Editor Thrombophilia Testing and Venous Thrombosis Jean M. Connors, M.D. Ordering thrombophilia tests is easy; determining whom to test and how to use the results is
More informationClinical Policy Title: Genetic testing for G1691A polymorphism factor V Leiden
Clinical Policy Title: Genetic testing for G1691A polymorphism factor V Leiden Clinical Policy Number: 05.01.03 Effective Date: January 1, 2016 Initial Review Date: July 15, 2015 Most Recent Review Date:
More informationThrombophilias: A Practical Approach
Disclosures Thrombophilias: A Practical Approach Speaker s Bureau: BMS/Pfizer (Apixaban) PI Altru Health System: EVE Trial Apixaban in Malignancy Keith E Swanson MD North Dakota Family Medicine Conference,
More informationChapter. A higher risk of recurrent venous thrombosis in men is due to hormonal risk factors in women in thrombophilic families
Chapter A higher risk of recurrent venous thrombosis in men is due to hormonal risk factors in women in thrombophilic families Willem M. Lijfering Nic J.G.M. Veeger Saskia Middeldorp Karly Hamulyák Martin
More informationSpontane und Tumor-assoziierte VTE: womit wie lange antikoagulieren
Spontane und Tumor-assoziierte VTE: womit wie lange antikoagulieren Paul Kyrle Allgemeines Krankenhaus Wien Disclosures relevant for this presentation Consultancies, member of advisory boards, speaker
More informationClinical Policy Title: Genetic testing for G1691A polymorphism factor V Leiden
Clinical Policy Title: Genetic testing for G1691A polymorphism factor V Leiden Clinical Policy Number: 05.01.03 Effective Date: January 1, 2016 Initial Review Date: July 15, 2015 Most Recent Review Date:
More informationFocus: l embolia polmonare Per quanto la terapia anticoagulante orale? Giulia Magnani 27 Gennaio, 2018
Focus: l embolia polmonare Per quanto la terapia anticoagulante orale? Giulia Magnani 27 Gennaio, 2018 NO DISCLOSURE Pulmonary Embolism Venous thromboembolism (VT) is the third most common cause of cardiovascular
More informationChanging the Ambulatory Training Paradigm: The Design and Implementation of an Outpatient Pulmonology Fellowship Curriculum
Online Data Supplement Changing the Ambulatory Training Paradigm: The Design and Implementation of an Outpatient Pulmonology Fellowship Curriculum Stacey M. Kassutto, C. Jessica Dine, Maryl Kreider, Rupal
More informationUPDATE ON TREATMENT OF ACUTE VENOUS THROMBOSIS
UPDATE ON TREATMENT OF ACUTE VENOUS THROMBOSIS Armando Mansilha MD, PhD, FEBVS 16 th National Congress of the Italian Society of Vascular and Endovascular Surgery Bologna, 2017 Disclosure I have the following
More informationIs Thrombophilia Testing Useful?
CONSULTATIVE HEMATOLOGY I: COMMON QUESTIONS IN THROMBOSIS CONSULTS Is Thrombophilia Testing Useful? Saskia Middeldorp 1 1 Department of Vascular Medicine, Academic Medical Center, Amsterdam, The Netherlands
More informationSession Chair: Andrew I. Schafer, MD Speakers: Mary Cushman, MD, MSc; Paolo Prandoni, MD, PhD; and Thomas L. Ortel, MD, PhD
Thrombosis II Session Chair: Andrew I. Schafer, MD Speakers: Mary Cushman, MD, MSc; Paolo Prandoni, MD, PhD; and Thomas L. Ortel, MD, PhD Inherited Risk Factors for Venous Thrombosis Mary Cushman Venous
More informationCanadian Society of Internal Medicine Annual Meeting 2016 Montreal, QC
Canadian Society of Internal Medicine Annual Meeting 2016 Montreal, QC 1 st workshop: update to VTE guidelines in 2016 2 nd workshop: VTE controversies + new horizons André Roussin MD, FRCP, CSPQ CHUM
More informationDVT Pathophysiology and Prophylaxis in Medically Hospitalized Patients. David Liff MD Oklahoma Heart Institute Vascular Center
DVT Pathophysiology and Prophylaxis in Medically Hospitalized Patients David Liff MD Oklahoma Heart Institute Vascular Center Overview Pathophysiology of DVT Epidemiology and risk factors for DVT in the
More informationNew Developments in VTE Treatment
Disclosures: Accommodation at this meeting funded by Boehringer Investigator in phase III studies of Rivaroxiban, Dabigatran, Edoxaban New Developments in VTE Treatment GPCME meeting, August, Dunedin Dr
More informationVENOUS THROMBOEMBOLISM: DURATION OF TREATMENT
VENOUS THROMBOEMBOLISM: DURATION OF TREATMENT OBJECTIVE: To provide guidance on the recommended duration of anticoagulant therapy for venous thromboembolism (VTE). BACKGROUND: Recurrent episodes of VTE
More informationThrombophilia testing: who is it good for? F.R. Rosendaal, Leiden
Thrombophilia testing: who is it good for? F.R. Rosendaal, Leiden Inaugural meeting of Iranian Society on Thrombosis and Haemostasis Mofid Children Hospital Tehran, 24 December 2015 Chest. 2012;141(2_suppl):e48S-e801S
More informationUnderstanding Best Practices in Anticoagulation Therapy in Patients with Venous Thromboembolism. Rajat Deo, MD, MTR
Understanding Best Practices in Anticoagulation Therapy in Patients with Venous Thromboembolism Rajat Deo, MD, MTR Director of Translational Research in Cardiac Arrhythmias Division of Cardiovascular Medicine
More informationRecurrence risk after anticoagulant treatment of limited duration for late, second venous thromboembolism
ARTICLES Coagulation & its Disorders Recurrence risk after anticoagulant treatment of limited duration for late, second venous thromboembolism Tom van der Hulle, Melanie Tan, Paul L. den Exter, Mark J.G.
More informationPrevention and treatment of venous thromboembolic disease
REVIEW Prevention and treatment of venous thromboembolic disease SUSAN McNEILL AND CATHERINE BAGOT Awareness of the risk factors for venous thromboembolic (VTE) disease and timely administration of thromboprophylaxis
More informationDiagnosis and Management of Hypercoagulabilty and the Direct Oral Anticoagulants: Interpreting the Data COPYRIGHT. Kenneth A.
Diagnosis and Management of Hypercoagulabilty and the Direct Oral Anticoagulants: Interpreting the Data Kenneth A. Bauer, MD kbauer@bidmc.harvard.edu Disclosures Janssen rivaroxaban BMS apixaban Boehringer
More informationEpidemiologia e clinica del tromboembolismo venoso. Maria Ciccone Sezione di Ematologia e Fisiopatologia della Coagulazione
Epidemiologia e clinica del tromboembolismo venoso Maria Ciccone Sezione di Ematologia e Fisiopatologia della Coagulazione Thrombophilia may present clinically as one or more of several thrombotic manifestations
More informationHow long to continue anticoagulation after DVT?
How long to continue anticoagulation after DVT? Dr. Nihar Ranjan Pradhan M.S., DNB (Vascular Surgery), FVES(UK) Consultant Vascular Surgeon Apollo Hospital, Jubilee Hills, Hyderabad (Formerly Faculty in
More informationCLINICIANS TEST FOR PROTHROMbotic
CLINICAL REVIEW CLINICIAN S CORNER Predictive Value of Factor V Leiden and Prothrombin G20210A in Adults With Venous Thromboembolism and in Family Members of Those With a Mutation A Systematic Review Jodi
More informationMolecular mechanisms & clinical consequences. of prothrombin mutations. A.J. Hauer
Molecular mechanisms & clinical consequences of prothrombin mutations A.J. Hauer 07-12-2018 Prothrombin & the coagulation cascade Coagulation factor II, thrombin. Prothrombin is synthesized in the liver
More informationCOAGULATION INHIBITORS LABORATORY DIAGNOSIS OF PROTHROMBOTIC STATES REGULATION OF. ANTICOAGULANT PROTEIN DEFICIENCY Disease entities COAGULATION
LABORATORY DIAGNOSIS OF PROTHROMBOTIC COAGULATION INHIBITORS Tissue Factor Pathway Inhibitor (TFPI) Lipoprotein Associated Coagulation Inhibitor (LACI) Extrinsic Pathway Inhibitor (EPI) Complexes with
More informationThrombosis. By Dr. Sara Mohamed Abuelgasim
Thrombosis By Dr. Sara Mohamed Abuelgasim 1 Thrombosis Unchecked, blood coagulation would lead to dangerous occlusion of blood vessels if the protective mechanisms of coagulation factor inhibitors, blood
More informationPE service. 65 years old lady. What would you do next? Risk stratification. What would you do next? Regional College Lecture PE Management
PE service Regional College Lecture PE Management Update in medicine (Eastern) Cambridge 29 th June 2017 Dr Rachel M Limbrey DM FRCP University Hospital Southampton NHS Foundation Trust Ambulatory acute
More informationPotpourri of Hematology Oncology. Jasmine Nabi, M.D. Oncology Associates Hall-Perrine Cancer Center at Mercy
Potpourri of Hematology Oncology Jasmine Nabi, M.D. Oncology Associates Hall-Perrine Cancer Center at Mercy Lifestyle Modifications to Decrease the Risk of Colorectal Cancer Estimates for 2018 American
More informationCADTH. August [Draft] Draft for Consultation 1
CADTH August 2014 [Draft] Effectiveness of Factor V Leiden and Prothrombin Mutation Testing in Patients Presenting with Unprovoked First Thromboembolic Episode: Systematic Review and Economic Analysis
More information10/24/2013. Heparin-Induced Thrombocytopenia (HIT) Anticoagulation Management in ECMO Therapy:
Anticoagulation Management in ECMO Therapy: Heparin-Induced (HIT) Michael H. Creer, MD Professor of Pathology Director, Clinical Laboratories, Medical Co- Director, Hematopathology and Chief, Division
More informationUpdates in Coagulation Thrombophilia testing and direct oral anticoagulants. Kevin Y. Chen, MD Hematology and Medical Oncology October 13, 2017
Updates in Coagulation Thrombophilia testing and direct oral anticoagulants Kevin Y. Chen, MD Hematology and Medical Oncology October 13, 2017 No conflicts of interest Introduction to thrombosis Hemostasis
More informationThursday, February 26, :00 am. Regulation of Coagulation/Disseminated Intravascular Coagulation HEMOSTASIS/THROMBOSIS III
REGULATION OF COAGULATION Introduction HEMOSTASIS/THROMBOSIS III Regulation of Coagulation/Disseminated Coagulation necessary for maintenance of vascular integrity Enough fibrinogen to clot all vessels
More informationComparison of Three Methods for Measuring Factor VIII Levels in Plasma
Coagulation and Transfusion Medicine / THREE FACTOR VIII ASSAYS Comparison of Three Methods for Measuring Factor VIII Levels in Plasma Wayne L. Chandler, MD, Chris Ferrell, MT(ASCP), Joo Lee, MT(ASCP),
More informationAntiphospholipid Antibody Syndrome: Management Issues for the Hematologist
Antiphospholipid Antibody Syndrome: Management Issues for the Hematologist Wisconsin Institute of Discovery Karen Rossi/Bristol-Myers Squibb Morey A. Blinder, MD Washington University, St. Louis, MO March
More informationResults from RE-COVER RE-COVER II RE-MEDY RE-SONATE EXECUTIVE SUMMARY
Assessment of the safety and efficacy of dabigatran etexilate (Pradaxa ) in the treatment of deep vein thrombosis (DVT) and pulmonary embolism (PE) and the prevention of recurrent DVT and PE Results from
More informationAbsence of the Factor V Leiden mutation and genetic risk for CTEPH
Absence of the Factor V Leiden mutation and genetic risk for CTEPH Mark W. Dodson, MD, PhD Assistant Professor, Pulmonary/Critical Care Intermountain Medical Center Murray, Utah A paradox in our current
More informationOptimizing diagnostic testing for venous thromboembolism
REVIEW CME CREDIT LEARNING OBJECTIVE: Readers will take a thoughtful approach to diagnosing venous thromboembolism and screening for thrombophilic disorders PATRICK RENDON, MD Assistant Professor, Department
More informationA Review of the Role of Non-Vitamin K Oral Anticoagulants in the Acute and Long-Term Treatment of Venous Thromboembolism
Cardiol Ther (2018) 7:1 13 https://doi.org/10.1007/s40119-018-0107-0 REVIEW A Review of the Role of Non-Vitamin K Oral Anticoagulants in the Acute and Long-Term Treatment of Venous Thromboembolism Andrew
More informationSinus and Cerebral Vein Thrombosis
Sinus and Cerebral Vein Thrombosis A Summary Sinus and cerebral vein clots are uncommon. They can lead to severe headaches, confusion, and stroke-like symptoms. They may lead to bleeding into the surrounding
More informationDOACs in SPECIAL POPULATIONS
DOACs in SPECIAL POPULATIONS Ann K Wittkowsky PharmD, CACP, FASHP, FCCP Clinical Professor University of Washington School of Pharmacy Director, Anticoagulation Services UWMedicine Department of Pharmacy
More informationThis chapter will describe the effectiveness of antithrombotic
Antithrombotic Therapy for Venous Thromboembolic Disease The Seventh ACCP Conference on Antithrombotic and Thrombolytic Therapy Harry R. Büller, MD, Chair; Giancarlo Agnelli, MD; Russel D. Hull, MBBS,
More informationLow-Molecular-Weight Heparin
Low-Molecular-Weight Heparin Policy Number: Original Effective Date: MM.04.019 10/15/2007 Line(s) of Business: Current Effective Date: HMO; PPO; QUEST Integration 05/01/2016 Section: Prescription Drugs
More informationVenous thromboembolism (VTE) consists of deep vein
Clinical Utility of Factor V Leiden (R506Q) Testing for the Diagnosis and Management of Thromboembolic Disorders Richard D. Press, MD, PhD; Kenneth A. Bauer, MD; Jody L. Kujovich, MD; John A. Heit, MD
More informationInternal Quality Control in the Haemostasis laboratory. Dr Steve Kitchen Sheffield Haemophilia and Thrombosis centre & UK NEQAS Blood Coagulation
Internal Quality Control in the Haemostasis laboratory Dr Steve Kitchen Sheffield Haemophilia and Thrombosis centre & UK NEQAS Blood Coagulation Why do we need Quality control? Philadelphia Enquirer Aug
More informationGuidance for the evaluation and treatment of hereditary and acquired thrombophilia
Guidance for the evaluation and treatment of hereditary and acquired thrombophilia The Harvard community has made this article openly available. Please share how this access benefits you. Your story matters
More informationLow Molecular Weight Heparin for Prevention and Treatment of Venous Thromboembolic Disorders
SURGICAL GRAND ROUNDS March 17 th, 2007 Low Molecular Weight Heparin for Prevention and Treatment of Venous Thromboembolic Disorders Guillermo Escobar, M.D. LMWH vs UFH Jayer s sales pitch: FALSE LMW is
More informationCover Page. The handle holds various files of this Leiden University dissertation.
Cover Page The handle http://hdl.handle.net/188/20915 holds various files of this Leiden University dissertation. Author: Flinterman, Linda Elisabeth Title: Risk factors for a first and recurrent venous
More informationVenous Thromboembolic Disease Update
Canadian Society of Internal Medicine Annual Meeting Calgary, Alberta, October 2014 Venous Thromboembolic Disease Update Benjamin Bell, MD FRCPC James Douketis, MD FRCPC On Behalf of Thrombosis Canada
More informationShould Patients with Venous Thromboembolism Be Screened for Thrombophilia?
REVIEW Should Patients with Venous Thromboembolism Be Screened for Thrombophilia? James E. Dalen, MD, MPH University of Arizona, Tucson. ABSTRACT In the mid-19th century, Virchow identified hypercoagulability
More informationThe Evidence Base for Treating Acute DVT
The Evidence Base for Treating Acute DVT Mr Chung Sim Lim Consultant Vascular Surgeon and Honorary Lecturer Royal Free London NHS Foundation Trust and University College London NIHR UCLH Biomedical Research
More informationPROGNOSIS AND SURVIVAL
CANCER ASSOCIATED THROMBOSIS PROGNOSIS AND SURVIVAL Since French internist Armand Trousseau reported the occurrence of mysterious thrombotic disorders in cancer patients in the mid-19th century, the link
More informationIl D-dimero: vantaggi e limiti
XXVI Congresso Nazionale FCSA Bologna 5-7 Novembre 2015 Il D-dimero: vantaggi e limiti Gualtiero Palareti Cardiovascular diseases University of Bologna, Italy Degradation of stabilized fibrin DD= Methodolgical
More informationClinical implications of deficiencies of protein S, protein C or antithrombin Brouwer, Jan Leendert Pouwel
University of Groningen Clinical implications of deficiencies of protein S, protein C or antithrombin Brouwer, Jan Leendert Pouwel IMPORTANT NOTE: You are advised to consult the publisher's version (publisher's
More informationDEEP VENOUS THROMBOSIS AMONG CARRIERS OF FACTOR V LEIDEN AND THE G20210A PROTHROMBIN MUTATION
DEEP VENOUS THROMBOSIS AMONG CARRIERS OF FACTOR V LEIDEN AND THE G20210A PROTHROMBIN MUTATION THE RISK OF RECURRENT DEEP VENOUS THROMBOSIS AMONG HETEROZYGOUS CARRIERS OF BOTH FACTOR V LEIDEN AND THE G20210A
More informationDisclosures. DVT: Diagnosis and Treatment. Questions To Ask. Dr. Susanna Shin - DVT: Diagnosis and Treatment. Acute Venous Thromboembolism (VTE) None
Disclosures DVT: Diagnosis and Treatment None Susanna Shin, MD, FACS Assistant Professor University of Washington Acute Venous Thromboembolism (VTE) Deep Venous Thrombosis (DVT) Pulmonary Embolism (PE)
More informationEDUCATIONAL COMMENTARY DISSEMINATED INTRAVASCULAR COAGULATION
EDUCATIONAL COMMENTARY DISSEMINATED INTRAVASCULAR COAGULATION Educational commentary is provided through our affiliation with the American Society for Clinical Pathology (ASCP). To obtain FREE CME/CMLE
More informationVenous thrombosis in unusual sites
Venous thrombosis in unusual sites Walter Ageno Department of Medicine and Surgery University of Insubria Varese Italy Disclosures Employment Research support Scientific advisory board Consultancy Speakers
More informationThrombophilia. Dr. A Sarrafnejad PhD Dep. Immunology School of public health TUMS
Autoimmune Thrombophilia Dr. A Sarrafnejad PhD Dep. Immunology School of public health TUMS Saraf@sina.tums.ac.ir Acquired Thrombophilia HIT PNH Cyckle cell Anemia Myeloproliferative lf Diseases Thrombocytosis
More informationCitation for published version (APA): van Vlijmen, E. F. W. (2016). The pill and thrombosis. [Groningen]: Rijksuniversiteit Groningen.
University of Groningen The pill and thrombosis van Vlijmen, Elizabeth Femma Willemien IMPORTANT NOTE: You are advised to consult the publisher's version (publisher's PDF) if you wish to cite from it.
More informationASH 2011: Clinically Relevant Highlights Regarding Venous Thromboembolism and Anticoagulation
ASH 2011: Clinically Relevant Highlights Regarding Venous Thromboembolism and Anticoagulation Stephan Moll Department of Medicine, Division of Hematology-Oncology, University of North Carolina School of
More informationThe latest on the diagnosis and treatment of venous thromboembolism
The latest on the diagnosis and treatment of venous thromboembolism Vicky Tagalakis MD FRCP Division of General Internal Medicine Jewish General Hospital McGill University Disclosures Advisory board Pfizer
More informationThromboembolism and cancer: New practices. Marc Carrier
Thromboembolism and cancer: New practices Marc Carrier Marc Carrier Research Support/P.I. Employee Consultant Major Stockholder Speakers Bureau Honoraria Scientific Advisory Board Leo Pharma, BMS No relevant
More informationCover Page. The handle holds various files of this Leiden University dissertation
Cover Page The handle http://hdl.handle.net/1887/37409 holds various files of this Leiden University dissertation Author: Engbers, Marissa Title: Conventional and age-specific risk factors for venous thrombosis
More informationThe risk of recurrence in women with venous thromboembolism while using estrogens: a prospective cohort study
Journal of Thrombosis and Haemostasis, 12: 635 640 DOI: 10.1111/jth.12528 ORIGINAL ARTICLE The risk of recurrence in women with venous thromboembolism while using estrogens: a prospective cohort study
More informationThe effect of the direct oral anticoagulants (DOACs) on haemostasis tests.
The effect of the direct oral anticoagulants (DOACs) on haemostasis tests. Emmanuel J Favaloro, Haematology, ICPMR, Pathology West, Sydney Centres for Thrombosis and Haemostasis, Westmead Hospital (with
More informationLupus Anticoagulants (LA), Antiphospholipid (APL) Antibodies & APL Syndrome: Review & Update. Antiphospholipid. Antiphospholipid
, Antiphospholipid (APL) Antibodies & APL Syndrome: Review & Update William L. Nichols, MD Mayo Clinic College of Medicine Rochester, Minnesota USA Disclosures & Objectives (Nichols) Disclosures Relevant
More informationMedical Patients: A Population at Risk
Case Vignette A 68-year-old woman with obesity was admitted to the Medical Service with COPD and pneumonia and was treated with oral corticosteroids, bronchodilators, and antibiotics. She responded well
More informationInsights from whole genome sequencing of a family with Venous Thromboembolism
Insights from whole genome sequencing of a family with Venous Thromboembolism Mariza de Andrade, PhD Professor of Biostatistics Division of Biomedical Statistics and Informatics Mayo Clinic, Rochester,
More informationWith All the New Drugs, This is How I Treat Acute DVT and Superficial Phlebitis
BRIGHAM AND WOMEN S HOSPITAL With All the New Drugs, This is How I Treat Acute DVT and Superficial Phlebitis Gregory Piazza, MD, MS Division of Cardiovascular Medicine Brigham and Women s Hospital April
More informationRecent studies have found that elevated levels of coagulation
Elevated Hemostatic Factor Levels as Potential Risk Factors for Thrombosis Wayne L. Chandler, MD; George M. Rodgers, MD, PhD; Jason T. Sprouse, MD; Arthur R. Thompson, MD, PhD Recent studies have found
More information